FibroGen (FGEN) Appoints David DeLucia as CFO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St recovers as yields ease; Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
H.C. Wainwright Starts FibroGen (FGEN) at Buy
December 17, 2024 7:57 AM ESTH.C. Wainwright analyst Matt Keller initiates coverage on FibroGen (NASDAQ: FGEN) with a Buy rating and a price target of $10.00.
The analyst comments "FibroGen's ADC pipeline could be a whole new ball game in mCRPC and beyond. We are initiating coverage of FibroGen with a Buy rating and $10 PT. FibroGens lead asset, FG-3246, is a novel antibody drug conjugate (ADC) targeting CD46 expressing tumors.... More
